Skip to main content
. Author manuscript; available in PMC: 2021 Feb 15.
Published in final edited form as: Cancer Res. 2020 Jun 19;80(16):3372–3382. doi: 10.1158/0008-5472.CAN-20-0056

Figure 4.

Figure 4

Effects of the treatment on the total number of the different cancer cell types (type-0: sensitive to both drugs, type-1: alpelisib-sensitive cells, type-2: neratinib-sensitive cells, total: the sum of type-0, type-1 and type-2 cells). The different dosing schedules explored are summarized in Table 2. A) Effect of four simulated dosing schedules on the number of resistant cells over time. B-E) Comparison of the different dosing schedules on the remaining fraction of cells after the treatment period (i.e. expected number of cancer cells after 30-day treatment divided by the initial number of cells before treatment administration): total number of cells (B), number of type-0 cells (C), number of type-1 cells (D) and number of type-2 cells (E). The bars represent the fraction of remaining cells whereas the numbers on top of the bars indicate the percent difference from the worst schedule; i.e. the highest bar represents the worst schedule while the shortest bar represents the best.